There are currently 53 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Advanced Cancer participants are Texas, California, Florida and New York.
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03129139
Recruiting
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +6 locations
Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Register for Updates
AIMS Cancer Outcomes Study
NCT04495790
Recruiting
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
Gender:
All
Ages:
All
Trial Updated:
01/30/2023
Locations: AIMS Institute, Seattle, Washington
Conditions: Neoplasms, Neoplasm Malignant, Advanced Cancer, Advanced Solid Tumor, Oncology
Register for Updates
A Study in Patients With Advanced Cancers
NCT05320588
Recruiting
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/15/2022
Locations: NEXT Oncology Austin, Austin, Texas +2 locations
Conditions: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Register for Updates
PEN-866 in Patients With Advanced Solid Malignancies
NCT03221400
Recruiting
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: Highlands Oncology Group, Springdale, Arkansas +15 locations
Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Register for Updates
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
NCT04859777
Recruiting
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors. The study will be conducted in 3 parts: Part A: MPT-0118 dose-escalation Part B: MPT-0118 dose-escalation in combination with pembrolizumab Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
09/15/2021
Locations: St. John's Cancer Center, Santa Monica, California +4 locations
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
Register for Updates